| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | CFO And COO
2 companies
Chevallard Daniel R. is a CFO And COO at Viracta Therapeutics, Inc. with holdings across 2 companies. Recent SEC Form 4 filings include 4 buys and 7 sells.
Estimated insider holdings value: $177K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | LENZ Lenz Therapeutics, Inc. | Chief Financial Officer | Buy | 7,500 | $8.57 | $64,275.00 | +139.2% | - | - | |
| Nov 7, 2025 | LENZ Lenz Therapeutics, Inc. | Chief Financial Officer | Buy | 2,198 | $22.76 | $50,016.99 | +34.4% | -39.2% | - | |
| May 14, 2024 | LENZ Lenz Therapeutics, Inc. | Chief Financial Officer | Buy | 3,188 | $15.68 | $49,987.84 | New | +47.5% | +75.8% | |
| Feb 27, 2024 | VIRX Viracta Therapeutics, Inc. | CFO And COO | Sale+OE | 3,405 | $0.73 | $2,493.14 | -3.2% | - | - | |
| Nov 28, 2023 | VIRX Viracta Therapeutics, Inc. | CFO And COO | Sale+OE | 3,720 | $0.50 | $1,860.00 | -3.6% | - | - | |
| Aug 28, 2023 | VIRX Viracta Therapeutics, Inc. | CFO And COO | Sale+OE | 3,512 | $1.45 | $5,092.40 | -3.5% | - | - | |
| May 25, 2023 | VIRX Viracta Therapeutics, Inc. | CFO And COO | Sale+OE | 3,635 | $1.42 | $5,160.25 | -3.8% | - | - | |
| Feb 27, 2023 | VIRX Viracta Therapeutics, Inc. | CFO And COO | Sale+OE | 3,599 | $1.68 | $6,050.64 | -3.9% | - | - | |
| Nov 28, 2022 | VIRX Viracta Therapeutics, Inc. | CFO And COO | Sale+OE | 3,532 | $2.72 | $9,605.63 | -4.0% | - | - | |
| Aug 26, 2022 | VIRX Viracta Therapeutics, Inc. | CFO And COO | Sale+OE | 3,655 | $4.02 | $14,679.21 | -4.2% | - | - |